Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

CNS Pharmaceuticals Inc CNSP

Healthcare
CNS Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company developing a pipeline of anti-cancer drug candidates for the treatment of primary and metastatic cancers of the brain and central nervous system (CNS). The Company's lead drug candidate, Berubicin, is a novel anthracycline and the first anthracycline to appear to cross the blood-brain barrier. Berubicin is in development for the treatment of a number of serious brain and CNS oncology indications, including glioblastoma multiforme (GBM), an aggressive and incurable form of brain cancer. In addition, the Company is advancing the development of its WP1244/WP1874 drug technology, which utilizes anthracycline and distamycin-based scaffolds to create small molecule agents. The Company is also evaluating the use of WP1244/WP1874 in the treatment of other primary brain and central nervous system cancers, as well as cancers metastatic to the brain including pancreatic, ovarian, and lymphomas.


NDAQ:CNSP - Post by User

CNS Pharmaceuticals Inc
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(229)
•••
Post by whytestockson Aug 22, 2024 1:30pm
31 Views
Post# 36192105

InvestorNewsBreaks - CNS Pharmaceuticals Inc.&#xA0;(NASDAQ:

InvestorNewsBreaks - CNS Pharmaceuticals Inc.&#xA0;(NASDAQ:
NEWS: $CNSP InvestorNewsBreaks - CNS Pharmaceuticals Inc.&#xA0;(NASDAQ: CNSP) CEO Featured in Upcoming Virtual Investor CEO Connect SegmentCNS Pharmaceuticals (NASDAQ: CNSP) , a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, will be spotlighted in this month&#x2019;s Virtual Investor CEO Connect. According to the announcement C...CNSP - InvestorNewsBreaks - CNS Pharmaceuticals Inc.&#xA0;(NASDAQ: CNSP) CEO Featured in Upcoming Virtual Investor CEO Connect Segment

<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities